Thermosensitive Periodontal Sol of Ciprofloxacin Hydrochloride and Serratiopeptidase: Pharmaceutical and Mechanical Analysis

Overview

Journal Int J Pharm Investig

Specialty Chemistry

Date 2014 Mar 29

PMID 24678456

Citations 5

Authors

Kushal Pal Singh

Gulshan Chhabra

Vijay Sharma

Kamla Pathak

Affiliations

Soon will be listed here.

Abstract

Aim: The aim of the present work was to explore the development of a dual-controlled release periodontal system of a potent broad spectrum first-generation fluoroquinolone, ciprofloxacin, and the anti-inflammatory enzyme serratiopeptidase (STP).

Materials And Methods: Based on 3(2) full factorial design, thermoreversible periodontal sols capable of controlled dual delivery of ciprofloxacin hydrochloride and STP were designed using pluronic F127 and carbopol 934P as thermosensitive gelling polymers. Sol gel transition characteristics, %cumulative drug release at 48(th) h and exvivo mucoadhesive strength were designated as dependent responses. The sols were mucoadhesive, syringeable, and inverted into gels at simulated periodontal cavity temperature.

Results: F9 with optimal drug release was identified as the best formulation. Extra design check point generated using Design Expert software 8.02 (Stat-Ease, USA) validated the experimental design. Textural analysis revealed that the developed sols were syringeable and spreadable enough for periodontal treatment so it can be expected that hardness and compressibility of sols would pose no problem during clinical application. The in vitro release behavior exhibited controlled release of both cipro HCl and STP (>90% release).

Conclusion: A dual-controlled release thermoreversible periodontal sol of ciproflaxin and STP was successfully developed. Incorporation of STP as anti-inflammatory agent has the potential of developing a therapeutically efficacious system of cipro HCl for treatment of periodontal inflammatory anaerobic infections.

Citing Articles

An up-to-date review of biomedical applications of serratiopeptidase and its biobetter derivatives as a multi-potential metalloprotease.

Hosseini S, Azizi M, Nojoumi S, Valizadeh V Arch Microbiol. 2024; 206(4):180.

PMID: 38502196 DOI: 10.1007/s00203-024-03889-6.

Development and In Vitro Characterization of Antibiotic-Loaded Nanocarriers for Dental Delivery.

Ghazwani M, Vasudevan R, Kandasamy G, Hani U, Niharika G, Naredla M Molecules. 2023; 28(7).

PMID: 37049683 PMC: 10096469. DOI: 10.3390/molecules28072914.

Healing Enhancement Assessment of Thermosensitive in Situ Gelling Formulation Containing Metronidazole and Diclofenac Potassium for Ligature-induced Periodontitis  in Rats.

Wadi N, Ahuja A, Peh K Oman Med J. 2022; 37(3):e381.

PMID: 35722242 PMC: 9194917. DOI: 10.5001/omj.2022.66.

Formulation and Evaluation of Eudragit RL-100 Nanoparticles Loaded In-Situ Forming Gel for Intranasal Delivery of Rivastigmine.

Salatin S, Barar J, Barzegar-Jalali M, Adibkia K, Alami-Milani M, Jelvehgari M Adv Pharm Bull. 2020; 10(1):20-29.

PMID: 32002358 PMC: 6983984. DOI: 10.15171/apb.2020.003.

Analytical techniques for serratiopeptidase: A review.

Gupte V, Luthra U J Pharm Anal. 2018; 7(4):203-207.

PMID: 29404039 PMC: 5790697. DOI: 10.1016/j.jpha.2017.03.005.

References

Slots J, Rams T . Antibiotics in periodontal therapy: advantages and disadvantages. J Clin Periodontol. 1990; 17(7 ( Pt 2)):479-93. DOI: 10.1111/j.1365-2710.1992.tb01220.x. View

Jain N, Jain G, Javed S, Iqbal Z, Talegaonkar S, Ahmad F . Recent approaches for the treatment of periodontitis. Drug Discov Today. 2008; 13(21-22):932-43. DOI: 10.1016/j.drudis.2008.07.010. View

Southard G, Godowski K . Subgingival controlled release of antimicrobial agents in the treatment of periodontal disease. Int J Antimicrob Agents. 1998; 9(4):239-53. DOI: 10.1016/s0924-8579(98)00004-1. View

Costa P, Sousa Lobo J . Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001; 13(2):123-33. DOI: 10.1016/s0928-0987(01)00095-1. View

Dodou K, Saddique W . Effect of manufacturing method on the in vitro drug release and adhesive performance of drug-in-adhesive films containing binary mixtures of ibuprofen with poloxamer 188. Pharm Dev Technol. 2011; 17(5):552-61. DOI: 10.3109/10837450.2010.550687. View

Das N, Madan P, Lin S . Statistical optimization of insulin-loaded Pluronic F-127 gels for buccal delivery of basal insulin. Pharm Dev Technol. 2011; 17(3):363-74. DOI: 10.3109/10837450.2010.542164. View

Abdel-Hamid S, Abdel-Hady S, El-Shamy A, El-Dessouky H . Formulation of an antispasmodic drug as a topical local anesthetic. Int J Pharm. 2006; 326(1-2):107-18. DOI: 10.1016/j.ijpharm.2006.07.028. View

Bansal K, Rawat M, Jain A, Rajput A, Chaturvedi T, Singh S . Development of satranidazole mucoadhesive gel for the treatment of periodontitis. AAPS PharmSciTech. 2009; 10(3):716-23. PMC: 2802163. DOI: 10.1208/s12249-009-9260-z. View

Lindhe J, Haffajee A, Socransky S . Progression of periodontal disease in adult subjects in the absence of periodontal therapy. J Clin Periodontol. 1983; 10(4):433-42. DOI: 10.1111/j.1600-051x.1983.tb01292.x. View

10.

Maheshwari M, Miglani G, Mali A, Paradkar A, Yamamura S, Kadam S . Development of tetracycline-serratiopeptidase-containing periodontal gel: formulation and preliminary clinical study. AAPS PharmSciTech. 2006; 7(3):76. PMC: 2750518. DOI: 10.1208/pt070376. View

11.

Gowrishankar R, Phadke R, Oza S, Talwalker S . Satranidazole: experimental evaluation of activity against anaerobic bacteria in vitro and in animal models of anaerobic infection. J Antimicrob Chemother. 1985; 15(4):463-70. DOI: 10.1093/jac/15.4.463. View

12.

Ruel-Gariepy E, Leroux J . In situ-forming hydrogels--review of temperature-sensitive systems. Eur J Pharm Biopharm. 2004; 58(2):409-26. DOI: 10.1016/j.ejpb.2004.03.019. View

13.

Amiji M, Shenoy D, Rao M . Intratumoral administration of paclitaxel in an in situ gelling poloxamer 407 formulation. Pharm Dev Technol. 2002; 7(2):195-202. DOI: 10.1081/pdt-120003487. View

14.

Bohorquez , KOCH , Trygstad , Pandit . A Study of the Temperature-Dependent Micellization of Pluronic F127. J Colloid Interface Sci. 1999; 216(1):34-40. DOI: 10.1006/jcis.1999.6273. View

15.

Loesche W, Syed S, Schmidt E, Morrison E . Bacterial profiles of subgingival plaques in periodontitis. J Periodontol. 1985; 56(8):447-56. DOI: 10.1902/jop.1985.56.8.447. View

16.

Haffajee A, Socransky S . Microbial etiological agents of destructive periodontal diseases. Periodontol 2000. 1994; 5:78-111. DOI: 10.1111/j.1600-0757.1994.tb00020.x. View

17.

Ur-Rehman T, Tavelin S, Grobner G . Chitosan in situ gelation for improved drug loading and retention in poloxamer 407 gels. Int J Pharm. 2011; 409(1-2):19-29. DOI: 10.1016/j.ijpharm.2011.02.017. View

18.

Vyas S, Sihorkar V, Mishra V . Controlled and targeted drug delivery strategies towards intraperiodontal pocket diseases. J Clin Pharm Ther. 2000; 25(1):21-42. DOI: 10.1046/j.1365-2710.2000.00261.x. View

19.

Hassan N, Ali M, Ali J . Novel buccal adhesive system for anti-hypertensive agent nimodipine. Pharm Dev Technol. 2009; 15(2):124-30. DOI: 10.3109/10837450903055494. View

20.

Dzink J, Tanner A, Haffajee A, Socransky S . Gram negative species associated with active destructive periodontal lesions. J Clin Periodontol. 1985; 12(8):648-59. DOI: 10.1111/j.1600-051x.1985.tb00936.x. View